This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Blood Cancer Awareness Month continues! Thank you to all who have contributed to our efforts to help raise awareness about CLL and other blood cancers. Please follow us on social media to learn more! As part of Blood Cancer Awareness Month, World Lymphoma Awareness Day is tomorrow, September 15th. CLL is a unique form of lymphoma where early diagnosis is not critical. But, here at CLL Society We Can’t Wait to support people living with chronic lymphocytic leukemia!
Upcoming CLL Society COVID-19 Event
COVID-19 Virtual Community Meeting: The Delta Variant and Staying Protected is taking place Friday, September 24th at 9:00 AM PT, 12:00 PM ET. The global COVID-19 pandemic continues in the U.S. due to the increased prevalence of the Delta variant coupled with suboptimal vaccination rates. It is critical that CLL patients and their caregivers continue to receive up-to-date and credible information from a spectrum of expert voices. This continuing series provides information to empower our CLL patient and caregiver community to make safe and informed decisions. CLL patients and caregivers can engage in a question-and-answer town hall format with a panel comprised of CLL experts Drs. Deborah Stephens and Nicole Lamanna, infectious disease expert Dr. Sanjeet Singh Dadwal, and virologist Daniel Engel, PhD.
We bet you have questions about the booster shot, monoclonal antibodies, testing for spike protein antibodies, and of course, the new variants, including Delta, Mu and others. At CLL Society, we feel duty-bound to do our best to secure credible, data-supported answers to your COVID-19 questions. We welcome your questions during the event, but also invite you to submit questions in advance to share with our speakers. To optimize our time, we can combine, rephrase, eliminate redundancies, and otherwise strategize to address the most succinct questions to specific panelists. This is your chance. So, ask away! Submit your questions to email@example.com. Don’t miss this important event.
CLL Society Ed Forum
Join us on October 15th for the CLL Society Ed Forum: The Right Tests at the Right Time to learn the basics about testing across the span of your CLL journey. Dr. Ryan Jacobs will discuss at the time of diagnosis, which tests should be performed, which might be avoided, and why. Dr. Brian Hill will discuss the importance of testing before starting your first treatment, and prior to every subsequent treatment. Know which tests you absolutely must have, which we strongly advise through CLL Society’s Test Before Treat™ campaign. Two patients will share their stories about the importance of getting the right tests completed prior to choosing treatment. Finally, learn how CLL is monitored over time, and how the evolving role of MRD (measurable residual disease) testing may help determine when to stop therapy for CLL.
To put into perspective why it’s important to be informed about testing prior to any treatment, Mark Hoffman shares how CLL Society resources and the Test Before Treat™campaign was integral to his receiving proper therapy for his CLL. Mark’s local community hematologist/oncologist recommended treating his CLL with chemotherapy. Sensing that this might be a poor choice, Mark opted for prognostic/ predictive testing, avoided chemotherapy, and is now uMRD. We invite you to read about Mark’s journey published by Cancer Health.
Special Article: Dr. Kerry Rogers on an Upcoming Phase I Clinical Trial of CDK9 Inhibitor VIP152 for Chronic Lymphocytic Leukemia (CLL)
Dr. Brian Koffman recently spoke with Dr. Kerry Rogers, assistant professor and hematologist in the Division of Hematology at the Ohio State University, about an upcoming phase I clinical trial of VIP152, a new cyclin-dependent kinase 9 (CDK9) inhibitor for patients with double refractory CLL or Richter’s syndrome. Ibrutinib (a Bruton’s tyrosine kinase inhibitor) and venetoclax (a BCL2 inhibitor) are both highly effective and tolerable treatments for CLL. However, over time patients can stop responding to these therapies, and there are even some patients who have developed resistance to both of these types of drugs. Once a patient is double refractory, there are still approved treatment options, but none have been shown to be highly effective. Patients may want to consider other options such as clinical trials with novel agents or cellular therapies such as CAR-T. Learn more here.
In Case You Missed it
The Global Oncology Initiative aims to organize City of Hope’s research community and expand local and global partnerships to tackle current and impending challenges in cancer and global health. On July 29, 2021, City of Hope’s Global Oncology Forum brought together the foremost clinical and research experts from City of Hope to expound on the epidemiology, virology, and prevention of COVID-19, including the Delta variant, risks to immunocompromised individuals and children under 12, vaccine delivery, boosters, and the latest findings about the coronavirus. The Global Oncology Forum on COVID19 recording is available here.
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.